source · text/markdown
source_1efa98274ede4b98
sha256 418ee7a9e593df1421a8b06cbee4e7e24b8add7c70018719d47211265bd1ae82
by researka:v2 · 2026-05-27 16:27:48.208578+04:00
The potential for aspirin to extend healthspan through anti-inflammatory, anti-thrombotic, and possibly anti-neoplastic mechanisms remains a compelling yet unresolved question in geroprotection research. This synthesis employed an AI-assisted structured evidence-synthesis approach with an auditable trail, systematically integrating 57 curated reference papers to map aspirin's geroprotective signals across disparate outcome classes including frailty, immunity, cardiometabolic risk, and safety. In a subgroup of ASPREE participants with diabetes, the incidence of frailty was context-dependent, indicating that baseline metabolic status may modify aspirin's trajectory effects in older adults (Espinoza 2025). Regarding immune modulation, aspirin has demonstrated preclinical potential to hasten resolution of skeletal muscle inflammation and promote recovery following acute injury (Lu 2026), yet human data are less consistent, with a pregnancy cohort showing increased tolerogenic CD56-bright NK cells but overall evidence remains mixed (Areia 2025). Across outcome classes, the synthesis surfaces cross-study disagreements, with positive signals in contextual cardiovascular settings but null or mixed findings dominating frailty, immune, and dosing pharmacokinetic domains. The mechanistic plausibility for aspirin-based geroprotection—via COX-mediated inflammatory resolution and platelet-dr
metadata
{
"article_type": "rapid_evidence_synthesis",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "064fba23-3fbd-4d15-b106-5a22bfdc3ca4",
"title": "Research Synthesis: Aspirin Geroprotection \u2014 full paper"
}